Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy

Indian Journal of Ophthalmology

Volumn 63, Issue 1, 2015, Pages 33-36

  Chernykh, V V ^a   Varvarinsky, E V ^a   Smirnov, E V ^a   Chernykh, D V ^a   Trunov, Alexander N ^a,b  

^a S FYODOROV EYE MICROSURGERY FEDERAL STATE INSTITUTION   (Russian Federation)

^b Research Institute of Experimental and Clinical Medicine   (Russian Federation)

Author keywords

Cytokines; diabetic retinopathy; pigment epithelium derived factor; vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; VASCULOTROPIN A;

DIABETIC RETINOPATHY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; VITRECTOMY; VITREOUS BODY;

BIOMARKERS; CYTOKINES; DIABETIC RETINOPATHY; EYE PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; RETROSPECTIVE STUDIES; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84923404777     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.151464     Document Type: Article

References (24)

1. Bhavsar AR. Diabetic retinopathy: The latest in current management. Retina 2006;26:S71-9.
2. Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and efective treatment. Dtsch Arztebl Int 2010;107:75-83.
3. Libman ES, Shakhova EV. Blindness and disability due to pathology of the organ of vision in Russia. Vestn Oftalmol 2006;122:35-7.
4. Lim A, Stewart J, Chui TY, Lin M, Ray K, Lietman T, et al. Prevalence and risk factors of diabetic retinopathy in a multi-racial underserved population. Ophthalmic Epidemiol 2008;15:402-9.
5. Balashevich LI, Brzheckij VV, Izmailov AS. In: Balashevich LI, editor. Ocular Manifestations of Diabetes. St. Petersburg: SPb MAPO; 2004. p. 382.
6. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: Current and emerging treatments. Clin Ophthalmol 2012;6:1325-33.
7. Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res 2012;47:7-12.
8. Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications 2012;26:435-41.
9. Pennock S, Kazlauskas A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol 2012;32:1955-66.
10. Wakabayashi Y, Usui Y, Okunuki Y, Ueda S, Kimura K, Muramatsu D, et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:6403-10.
11. Chernykh VV, Lysikov AG, Obukhova OO, Gorbenko OM, Shvayuk AP, Trunov AN. Features of local immune and inflammatory processes in non-proliferative diabetic retinopathy. Bull Novosibirsk State Univ 2011;9:164-8.
12. Khodjaev NS, Chernykh VV, Romenskaya IV, Kuntysheva KE, Trunov AN. Efects of laser retinal photocoagulation on clinical and laboratory parameters in patients with diabetic macular edema. Bull Novosibirsk State Univ 2011;9:48-53.
13. Kowluru RA, Zhong Q, Kanwar M. Metabolic memory and diabetic retinopathy: Role of inflammatory mediators in retinal pericytes. Exp Eye Res 2010;90:617-23.
14. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina 2008;28:817-24.
15. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55:256-63.
16. Symeonidis C, Papakonstantinou E, Androudi S, Rotsos T, Diza E, Brazitikos P, et al. Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy. Cytokine 2011;54:212-7.
17. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Goto H, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 2010;30:339-44.
18. Matsuoka M, Ogata N, Minamino K, Matsumura M. Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol 2006;50:116-20.
19. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-53.
20. Regan DP, Aarnio MC, Davis WS, Carmichael KP, Vandenplas ML, Lauderdale JD, et al. Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis. Vet Ophthalmol 2012;15:145-52.
21. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011;22:83-9.
22. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999;82:765-70.
23. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, et al. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40.
24. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Iwasaki T, et al. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina 2011;31:1951-7.